ArticleEye (London, England)2025
Symptom-based stratification of heterogeneous symptoms of dry eye disease in patients with Sjögren's syndrome.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveWe aimed to use symptom-based stratification to identify the subtype-specific pathophysiology of dry eye disease (DED) in Sjögren's syndrome (SS).
methodsWe retrospectively enrolled patients with SS who visited Juntendo University Hospital between October 2017 and July 2023 and were diagnosed with DED (2016 Asia Dry Eye Society guideline). The DED subtype and pathophysiology were classified under five distinct tear film breakup patterns: area, line, spot, dimple, and random breaks. Based on responses to the Japanese version of the Ocular Surface Disease Index (J-OSDI), spectral clustering was used to stratify participants; inter-cluster comparison of J-OSDI total scores and key DED-related objective findings was undertaken.
resultsAmong the 239 participants, DED prevalence was the highest in Cluster 3 (98.2%), followed by clusters 2 (83.4%) and 1 (4.1%). J-OSDI total scores were the highest in Cluster 3 (64.6 points) and lowest in Cluster 1 (2.1 points) (P < 0.001). Prevalence of line and area breaks (aqueous-deficient type) was highest in Cluster 1 (81.6%) whereas dimple and spot breaks (decreased-wettability type) were most prevalent in Cluster 2 (21.0%). Random breaks (increased evaporation) were observed most frequently in Cluster 1 (8.2%). Median MBI was shortest in Cluster 3 (7.1 s), followed by Cluster 2 (8.6 s) (P = 0.003). The median serum anti-SS-A/Ro concentration was highest in Cluster 3 (32.0 U/mL; P = 0.018). Cluster 2 showed a notable discrepancy between subjective symptoms and CFS scores.
conclusionsUsing symptom-based DED severity of SS, we successfully stratified patients into three clusters to potentially facilitate type-customised interventions to improve treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.